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Abstract 
Acute leukaemias as a group are the most common childhood malignancies and 
continue to be an important cause of non-accidental childhood mortality. Fortunately, 
with modern chemotherapy the majority of children and young people with leukaemia 
can be cured. However, this treatment comes with a significant burden for our young 
patients and their families. Here, we review the essential and differential diagnostics 
and the initial management of children with suspected leukaemia, as relevant for 
secondary paediatric care. We will give a short overview of current treatment 
protocols for childhood acute lymphoblastic and acute myeloid leukaemia. We will 
explain how stratification according to certain prognostic factors, most importantly 
response to therapy, guides treatment intensity. Using modern molecular techniques 
for minimal residual disease monitoring and molecular disease classification, it is 
increasingly possible to identify patients with a cure rate well above 90% in whom a 
reduction in treatment intensity may seem feasible. In addition, these techniques also 
allow definition of poor risk patients who may benefit from more intensive 
chemotherapy and bone marrow transplantation. Finally, we discuss long-term 
follow-up of survivors of childhood leukaemia as a multidisciplinary paediatric team 
approach as well as the challenges of transition into adult care.
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Introduction 
As a group, leukaemias represent the most common malignant conditions of 
childhood, with acute lymphoblastic leukaemia (ALL), the most common single 
condition, representing approximately 25% of malignant diagnoses in childhood.  As 
such they are an important cause of morbidity and mortality for children in the UK 
and abroad.  Treatment regimens may be lengthy and success requires enormous 
dedication from the child, their family and the family’s extended social network. 
Nevertheless, acute leukaemia provides a paradigm for the development of Paediatric 
Haematology and Oncology over the last 40 years.  It highlights the importance and 
power of nationally and increasingly internationally co-ordinated clinical trials to 
improving the outcome for children with rare conditions.  Almost universally fatal as 
recently as the 1960’s, acute lymphoblastic leukaemia now has an overall survival of 
above 80%.  Despite this success story, the twin challenges remain of improving 
survival for the 15-20% of children who relapse following first line therapy, whilst 
reducing the burden of therapy on the 50% of children who would previously have 
been cured by less intensive regimens.   
Significant improvements have also been made in the care of children with acute 
myeloid leukaemia. Whilst progress has been made, improving overall survival in 
children with myeloid leukaemia, towards the proportion cured in acute lymphoblastic 
leukaemia, remains a key target. Other, rarer conditions including chronic myeloid 
leukaemia and myelodysplasias are seen occasionally in children, but will not be 
discussed further in this review. 
Epidemiology 
In Europe, the incidence of acute lymphoblastic leukaemia in children aged 0-14 
years is 35 cases per million children per year, representing approximately 370 
children diagnosed each year in the UK.  Boys are slightly more frequently affected 
than girls (sex ratio 1.3:1).  The incidence in the UK and Europe has been slowly 
rising by approximately 0.8% per year between 1978 and 1997.   
Acute myeloid leukaemia (AML) is rather less common, affecting 6.5 children per 
million per year, or approximately 90 children per year in the UK.  Boys are again 
slightly more frequently affected than girls (ratio 1.2:1).  
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Aetiology 
Pioneering work by Professor Mel Greaves has shown that in many childhood 
leukaemias the malignant development starts before birth and the leukaemias 
originate in a foetal cell.  Clones harbouring the most common genetic mutations, 
TEL-AML1 and high hyperdiploidy, are identifiable in umbilical cord blood and 
Guthrie card blood spots following delivery.  It has been speculated that the 
occurrence of these genetic aberrations may be linked to prenatal exposure of 
ubiquitously present, natural DNA damaging substances.  However, no clear 
causative agent has yet been identified.  Reassuringly, both concordance studies in 
twins and studies looking at the prevalence of these mutations in the background 
population indicate that only a small minority go on to develop leukaemia, implying a 
necessary and infrequent (perhaps in one per hundred predisposed children) “second 
hit” or hits. 
The nature and cause of these additional hits is the focus of ongoing research.  In the 
case of TEL-AML1-positive ALL this is often the deletion of the remaining normal 
TEL allele.  In addition, frequent deletions of B cell transcription factors have 
recently been described and may play a key role in leukaemic development and 
progression, see further reading. 
Significant epidemiological data support the theory that a delayed exposure and/or an 
abnormal response to childhood infection may facilitate the postnatal malignant 
transformation in acute lymphoblastic leukaemia.  Evidence in support of this shows 
that regular attendance at day care in the first year of life, used as a proxy for early 
exposure to infections, reduces the risk of developing acute lymphoblastic leukaemia.   
Other putative risk factors including exposure to overhead power lines and 
intramuscular vitamin K in neonates have not been demonstrated to relate to the 
incidence of acute leukaemia. 
A small proportion of acute leukaemia develops in children with an identifiable 
constitutional genetic disorder.  By far the most common of these is Down syndrome 
which confers a 200 times increased risk of megakaryoblastic (M7) acute myeloid 
leukaemia in infants and a 20 times increase in acute lymphoblastic leukaemia at all 
age groups.  Myelodysplastic syndrome and AML may be preceded by a condition 
peculiar to newborn children with Down syndrome called transient myeloproliferative 
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disorder (TMD).  Seen in approximately 10% of newborns with Down syndrome, 
TMD is characterised by the presence of a clonal proliferation of megakaryoblasts in 
their peripheral blood.  Whilst the majority recover spontaneously, some 20% will 
subsequently develop AML. 
Pathophysiology 
Acute lymphoblastic leukaemia and acute myeloid leukaemia are defined by the 
uncontrolled proliferation of immature cells of lymphoid (B or T) or myeloid lineages 
respectively.  The cell of origin in which the different leukaemias arise is still subject 
to scientific debate.  The most common form of childhood leukaemia, B cell precursor 
ALL, appears to originate in a foetal B cell precursor; however, the evidence is 
indirect as it is difficult to model and study the first steps of human leukaemiogenesis.  
Related to the cell of origin is the question “Which are the cells that maintain the 
leukaemia?” - the so called leukaemic stem cells.  Until recently, it has been thought 
that, like in normal haematopoiesis, all types of leukaemias are maintained by a small 
population of highly specialised stem cells.  More recently, evidence is accumulating 
– in particular for childhood B cell precursor ALL – that many blasts at different 
stages of maturation may be able to propagate the leukaemia.  Therefore, leukaemic 
stem cells may be more frequent than previously thought.  To understand the 
mechanisms by which a population of cells maintain the leukaemic clone in our 
patients, is crucial for future drug development and is currently the focus of intense 
research. 
Presentation 
In practical terms, the pathophysiology and thus the clinical symptoms and signs can 
be explained by proliferation of the leukaemic cells within the bone marrow and other 
organs of the children, Box 1. 
Whilst many children are not critically unwell at presentation, certain findings require 
prompt action.  Significant respiratory compromise may result from either profound 
anaemia with or without cardiac failure, mediastinal obstruction or respiratory 
infection.  These patients are often critically ill and need careful interdisciplinary 
management.  The same is true of the small number of children with very high white 
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cell counts (>>100 X 109/l) who are at risk of leukostasis, and resultant neurological 
and cardio-respiratory events.   
Children presenting with leukaemia are conventionally considered to be 
immunocompromised, whatever their full blood count results. Febrile illness should 
be managed as for febrile neutropenia.  The presence of headaches, meningism or 
cranial nerve dysfunction raises the concern of central nervous system involvement.  
In boys, testicular involvement results in painless enlargement of a testis. 
Immediate management 
Essential diagnostics 
Essential diagnostic investigations are aimed at confirming the diagnosis of acute 
leukaemia and investigating for the complications, which may exist at presentation.  
These are: 
• Full blood count and peripheral blood film – malignant blasts may be present 
in peripheral blood and may even be immunologically assessed by flow 
cytometry 
• Coagulation studies – to exclude disseminated intravascular coagulation 
• Serum biochemistry – identify tumour lysis syndrome; ↑K+, ↑PO4-, ↑urate, 
↑urea/creatinine, ↓Ca2+ plus baseline liver function tests and lactate 
dehydrogenase 
• Chest radiograph – to exclude mediastinal involvement 
If acute leukaemia is suspected, the nearest Paediatric Haematology/Oncology referral 
centre should be contacted to discuss further investigation and management. 
Initial intervention 
Conventionally, immediate management consists of preventing the life-threatening 
complications of leukaemia.   
• Avoid tumour lysis syndrome – dependent on white cell count, serum 
electrolytes, renal function, LDH and urate, commence potassium-free 
hydration (3 l.m-2/24 h, maximum 4 l/24 h) plus allopurinol or urate oxidase 
(e.g. Rasburicase) 
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• Consider broad spectrum antibiotics in the presence of fever, focal signs of 
infection or if significantly unwell 
• Cautious transfusion, avoiding hyperviscosity syndrome, having taken base-
line viral serology tests (see below).  If clinically justifiable, blood product 
transfusion should be avoided prior to discussion with a Paediatric 
Haematology/Oncology department.  Children with significant anaemia who 
are at risk of developing cardiac failure should be transfused and stabilised 
before transfer to the Paediatric Haematology/Oncology department. 
• Correction of coagulopathy may be required and should be conducted in 
consultation with an experienced haematologist 
• Sedation or general anaesthesia risk obstruction of the airway and/or vena 
cava superior in a child with a mediastinal mass and should be avoided if at 
all possible.   
Further management following referral 
Following referral to a Paediatric Haematology/Oncology unit, a number of specific 
investigations will be performed to clarify the leukaemia type at the morphological, 
immunological and genetic level, and to determine the presence of central nervous 
system involvement.  Also performed are baseline investigations to allow for 
subsequent disease monitoring and assessment of treatment related complications.  
Once completed, discussion and initiation of anti-leukaemic therapy becomes the 
primary goal. 
• Bone marrow aspirate and trephine biopsy – this key diagnostic investigation 
will usually exclude differential diagnoses, see Box 2. 
• Lumbar puncture to assess central nervous system involvement – this is 
commonly performed under general anaesthetic for the child’s comfort and to 
help avoid a traumatic/blood stained tap which would make assessment of 
central nervous system disease difficult, and may result in upstaging of CNS 
status.  If the diagnosis has already been made, delivering the first intrathecal 
chemotherapy should be considered at this point. 
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• Flow cytometric immunophenotyping to determine cell lineage and maturity 
(e.g. B precursor ALL, T cell ALL), and to define the leukaemia associated 
immunophenotype for flow based minimal residual disease (MRD) monitoring  
• Cytogenetics and molecular genetics to identify high risk patients, allow 
treatment stratification and consideration of molecularly targeted therapy 
• Molecular determination of clonotypic immunoglobulin and T cell receptor 
rearrangements and/or flow cytometric determination of leukaemia-associated 
immunophenotypes, allowing future assessment of treatment response by 
minimal residual disease monitoring (see below) 
• Baseline viral serology (prior to transfusion of blood products) to assess 
immunity/exposure to e.g. varicella, measles, cytomegalovirus and herpes 
simplex virus etc.  This allows informed decision making in the event of 
exposure to these viruses or if allogeneic bone marrow transplantation is later 
required.  Some centres use this opportunity to screen for transmissible blood 
borne viruses, although this is not routinely recommended in the UK. 
• Baseline cardiac assessment with echocardiogram, particularly if a child is 
likely to receive higher cumulative doses of cardiotoxic anthracyclines, as 
used in AML therapy. 
 
Leukaemia specific management 
Childhood acute lymphoblastic leukaemia 
Modern anti-leukaemic therapy in ALL is based on systemic multi-drug 
chemotherapy plus CNS-directed therapy and usually employed in a risk-adapted 
fashion.  
Multidrug chemotherapy prevents development of drug resistance by the leukaemia.  
Chemotherapy agents included in most modern ALL treatment protocols (such as the 
current UK trials run by the Leukaemia Division of the Children’s Cancer & 
Leukaemia Group) are steroids (dexamethasone or prednisone), vincristine, 
methotrexate, asparaginase, cytarabine, cyclophosphamide, daunorubicin, and 6-
mercaptopurine.  Treatment protocols usually employ a period of intensive remission 
induction, consolidation and re-induction/delayed intensification (lasting 
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approximately six to twelve months in total) followed by protracted, mainly oral, 
maintenance chemotherapy for 2 -3 years. 
It has long been known that there are a number of sanctuary sites in which leukaemic 
blasts can escape systemic chemotherapy. These include the CNS (plus the eye) and 
testes in boys. Studies in the 1960’s and 70’s had shown that while systemic 
combination chemotherapy was effective in inducing remission, many patients would 
eventually relapse in the CNS although their initial lumbar puncture had not shown 
any evidence of leukaemia. In the seventies, CNS therapy consisted of cranial (and 
spinal) irradiation.  Due to the long term cognitive consequences (learning difficulties, 
concentration deficit, impaired executive functioning) of cranial irradiation 
particularly in smaller children alternative strategies were developed. Methotrexate 
given intrathecally via lumbar puncture (or Omaya type reservoirs into the ventricular 
system) was initially tried in conjunction with reduced doses of radiotherapy and then 
alone or in combination with high dose systemic methotrexate and (German BFM 
approach). This led to relapse rates similar to those found with cranial radiotherapy 
but with a reduction in long term intellectual effects. Dexamethasone with its better 
CNS penetration as compared with prednisone has also been shown to be beneficial in 
preventing CNS relapses (UK CCLG experience). The discontinuation of cranial 
irradiation was one of the major milestones in the development of modern ALL 
chemotherapy and has significantly reduced the unwanted long-term effects of ALL 
treatment.  
Risk stratification 
To avoid over treatment, reduce side effects for patients with a high chance for cure 
and to avoid under treatment for high-risk patients, modern treatment protocols 
employ risk-adapted stratification systems to allocate patients to treatment arms of 
different intensity.  Risk stratifiers include the NCI consensus criteria of age and cell 
count as well as leukaemia cytogenetics.  However, the most important risk factor in 
childhood ALL is response to therapy.  The German BFM group had shown that 
response in the peripheral blood following 7 days of prednisone treatment (combined 
with one intrathecal methotrexate injection) is the most important predictor of relapse.  
Similarly, UK protocols assess response to treatment by bone marrow aspiration and 
morphological analysis at day eight, +/- day 15 and day 28 of induction.  More 
recently, monitoring of minimal residual disease by sensitive, quantitative PCR of 
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leukaemia-specific immunoglobulin and T cell receptor gene rearrangements after 4 
and 11 weeks of therapy has shown to be highly predictive for relapse, see further 
reading.  Using this new tool, it has been possible to identify subgroups of patients 
with a cure rate well above 90% that may benefit from further treatment reduction.  In 
addition, it has been possible to identify patients with a very high risk for relapse that 
may benefit from additional treatment intensification and allogeneic bone marrow 
transplantation in first remission. 
Infant acute lymphoblastic leukaemia 
Children aged less than one year at diagnosis are treated on a slightly different 
protocol to older children. They have a very high incidence of ALL with 
translocations involving the MLL gene and traditionally responded poorly to standard 
ALL therapy. Modern treatment protocols for children with infant ALL combine 
chemotherapy blocks developed for the treatment of ALL and AML including a 
prolonged ALL style maintenance therapy. This hybrid therapy has led to a significant 
improvement in outcome for these patients.  
Acute myeloid leukaemia 
Therapy for AML consists of remission induction therapy followed by post-remission 
chemotherapy. The aim of induction therapy is to reduce the leukaemic clone to 
below the limit of morphological detection and restore normal haematopoiesis. Most 
induction chemotherapy is modelled after the original “7 and 3” Cancer and Leukemia 
Group B (CALGB) schedule that consisted of 7 days continuous infusion of 
cytarabine combined with 3 doses daunomycin. Most paediatric induction protocols 
add a third chemotherapeutic drug, e.g. etoposide, to cytarabine and daunomycin 
(ADE chemotherapy).  Often this induction protocol is repeated twice (double 
induction). 
Post remission chemotherapy consists of 2 -3 blocks of either consolidation therapy or 
intensification therapy. In particular, re-induction therapy with high dose cytarabine 
has been shown to be a very effective post remission chemotherapy block that 
improves survival of patients with AML.  It is particularly important for the treatment 
of children, as cytarabine based post remission chemotherapy may help to reduce the 
cumulative dose of anthracyclines, and thus late cardiotoxicity, in survivors of 
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paediatric AML. Unlike in ALL, prolonged maintenance chemotherapy does not seem 
to be beneficial in preventing relapses. 
Most paediatric AML trials include CNS directed therapy, mainly intrathecal 
injections with either cytarabine or a triple combination with cytarabine, methotrexate 
and hydrocortisone. 
The role of signal transduction inhibitors (e.g. FLT3 inhibitors) and other 
experimental drugs (e.g. antibodies such as Mylotarg) in treating AML in children is 
unclear and their application should be limited to clinical trials. Bone marrow 
transplantation is usually reserved for relapse patients.  
Two specific subgroups:  
Acute promyelocytic leukaemia (APL) with rearrangement of the retinoid receptor 
responds to differentiation therapy with ATRA and arsenic and is associated with an 
excellent outcome. ATRA (and arsenic) are integral part of modern primary and 
relapse treatment of APL and have helped reducing the early death rate due to 
disseminated intravascular coagulopathy in this subtype. Caution: differentiation 
therapy is associated with specific side effects (ATRA syndrome). 
Children with Down syndrome and AML have a much better response to treatment 
than other children.  This seems to be due to a marked sensitivity of the trisomy 21 
AML blasts to cytarabine, the key constituent of AML therapy in children with Down 
syndrome. Cytarabine-based treatment protocols with reduced anthracyclines have 
significantly improved outcome of these patients with a high risk of anthracycline-
related cardiotoxicity. These children are also at much higher risk of life threatening 
infection and require pro-active management of febrile episodes. 
Treatment related complications 
The majority of complications seen after presentation are related to treatment, rather 
than the primary disease.  These can be considered as: effects resulting from the 
majority of cytotoxic therapies (although varying in likelihood); effects specific to 
drugs or classes of drugs, Box 3.  Some will manifest during treatment and may 
require modification of a treatment plan, whilst others may not become apparent until 
many years after therapy has ended. 
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Amongst these, the most frequent side effects are temporary alopecia and 
myelosuppression.  Febrile neutropenic episodes are not uncommon and all families 
are taught to monitor temperatures and discuss concerns with their local paediatric 
unit.  Guidelines for medical review and management vary between centres.  This 
potentially life threatening condition is always treated urgently.  Empirical broad 
spectrum antibiotics should be started immediately following review and collection of 
clinical specimens.   Regular administration of cotrimoxazole is aimed at preventing 
pneumocystis (carinii) jiroveci pneumonia infection, one of the key, and yet 
preventable, causes of death in children with leukaemia.  Prophylaxis is continued 
throughout treatment until immune recovery, commonly three months after cessation 
of therapy.  Whilst infertility is uncommon with modern anti-leukaemic protocols, 
premature ovarian failure is increasingly recognised in cancer survivors and included 
in survivorship counselling. 
The most common drug specific complications are those associated with 
dexamethasone and vincristine.  Dexamethasone use is associated with mood 
disturbance, proximal myopathy, diabetes mellitus, hypertension, acne and avascular 
necrosis.  Most frequent, and commonly very distressing for children and families, are 
the pronounced temper tantrums, depression, sleep disturbance and hyperphagia 
experienced during the prolonged steroid course immediately following diagnosis.  
Most of these side effects are reversible, but significant and permanent bone or joint 
damage can result from avascular necrosis.  Vincristine toxicity results in peripheral 
neuropathy with weakness, neuropathic pain (classically jaw pain) and constipation.  
Practically all patients loose their tendon reflexes, foot drop is frequently seen and in 
some children their mobility is so badly affected that they come off their feet and 
require a wheelchair. Often these effects are aggravated by the concomitant presence 
of a dexamethasone-induced proximal myopathy. A number of patients will require 
specific neuropathic pain relief with drugs such as gabapentin, in addition to simple 
analgesics. Whilst the neuropathy is largely recoverable (except for the more severe 
manifestations), care needs to be taken to prevent contractures, most commonly 
resulting in tightening of the Achilles tendons. 
Another potentially very serious complication for immunosuppressed children is viral 
infections, particularly varicella and, less frequently, measles infection.  Presenting 
either as shingles, as primary or secondary disseminated chickenpox, or occasionally 
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with visceral involvement alone, immunosuppressed children are at significant risk of 
severe varicella infection.  A small minority will have a life threatening disease.  
Suspected or proven disease is treated aggressively with high dose intravenous 
acyclovir.   
Exposure to measles is less common, but equally important.  Every attempt to clarify 
the contact’s diagnosis should be made.  Definite significant contact or contact where 
the diagnosis seems plausible and cannot be virologically investigated may require 
passive immunisation with immunoglobulin.  
Relapse management 
Approximately 15-20% of children treated for ALL, and 40% treated for AML, will 
experience disease relapse.  The majority will happen following cessation of 
treatment, but a small number of children will relapse on, or soon after completing, 
treatment.  Such early relapse is associated with a significantly worse prognosis.  
Defining clearly the extent of the relapse, in terms of medullary versus extramedullary 
involvement and CNS or testis involvement is important to further define prognosis 
and treatment strategy.  The initial presentation, diagnosis and emergency 
management of relapse disease is broadly similar to that at primary diagnosis, 
although a small number of relapses may initially be identified in asymptomatic 
children having a full blood count during follow up.  
Treatment options include further standard chemotherapy and bone marrow 
transplantation, both of which offer the chance of cure, unlike in many other relapsed 
malignancies.  In addition some patients with multiple relapses may qualify for phase 
I/II trials with novel experimental drugs. Conditioning regimens and donor selection 
for transplantation are key decisions aimed at balancing engraftment, graft versus 
leukaemia effect and toxicities, including graft versus host disease.  It is beyond the 
scope of this review to discuss these decisions or the complex package of care 
provided by paediatric bone marrow transplantation centres. 
Immunisation 
An immunisation history and clinical history of chickenpox and measles should be 
sought at presentation, supplemented by serological testing according to local policy.  
This will frequently involve varicella, measles and CMV testing.  Standard 
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chemotherapy for leukaemia (i.e. not high dose chemotherapy and stem cell 
transplantation) is not an indication to delay the universal childhood immunisation 
schedule.  Indeed, immunocompromised children are in greater need of immune-
protection and children on treatment should therefore continue the universal schedule, 
excluding any live vaccines such as MMR/BCG/OPV, according to Royal College 
guidance (see further reading).  Furthermore, children receiving chemotherapy or 
within six months of treatment should receive influenza vaccination each autumn. 
As response to vaccination may be sub-optimal during chemotherapy administration, 
it is recommended that an additional booster be given to all children, six months 
following treatment. 
The use of varicella vaccination in immunocompromised children or their siblings is 
not universally recommended in the UK but may be considered in individual cases.   
Long term monitoring and late effects follow-up 
Following the end of treatment, children will remain under the follow-up of their 
Paediatric Haematology/Oncology specialist team for many years.  Indeed, many 
teams will continue to see young adults who completed treatment in early childhood.  
In part this is due to the current lack of transitional care for survivors of childhood 
malignancy, and in part to a recognition of the importance of long-term follow-up to 
optimising the care of both survivors and future patients.  The principle aims of 
prolonged follow-up are: 
• Surveillance for disease relapse – focused during the earlier period post 
therapy but risk remains for many years, especially in acute lymphoblastic 
leukaemia 
• Surveillance for secondary malignant disease – the principle risk of secondary 
malignancy exists following cranial or total body irradiation.  Patients are 
notably at increased risk of developing breast, brain, thyroid and skin 
malignancies.  Secondary haematopoietic malignancies may follow the use of 
certain chemotherapeutic agents, notably etoposide or alkylating agents. 
• Active assessment of therapy induced late effects – the critical importance of 
this area of follow-up has increasingly been recognised with the establishment 
of dedicated programmes/clinics, often run with a specialist nursing and wider 
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interdisciplinary team approach.  Premature ovarian failure and anthracycline 
induced cardiotoxicity are notable examples which may present 15-20 years, 
or later, after initial therapy. 
Survivors of paediatric malignancy stand-out within the wider field of oncology by 
virtue of their life expectancy.  Recent studies suggest a substantially increased risk of 
death compared to age matched controls even 20 years following treatment for 
leukaemia.  However, it is important not only to know the risk of e.g. cardiotoxicity 
10 or 20 years after anthracycline therapy, but also the risk of toxicity 30 and 40 years 
following treatment.  Individuals, early in their working lives, physically active and 
starting families of their own may benefit from a currently undefined level of 
education, monitoring and primary preventative therapy.  The structured collection 
and analysis of this information is essential both to optimise the health of survivors of 
childhood leukaemia and inform the treatment of future patients. 
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Practice Points 
• Molecular techniques have revolutionised our understanding of childhood 
leukaemia (prenatal origin; frequent deletions of B cell transcriptions factors 
in ALL) 
• Response to treatment as measured by minimal residual disease monitoring 
allows stratification of treatment intensity according to prognosis (at least in 
ALL) 
• Children with relapsed leukaemias often have a second chance for cure with 
chemotherapy usually followed by bone marrow transplantation 
• Despite the current success more tailored treatments with fewer side effects 
are needed for the treatment of childhood leukaemia as the burden of treatment 
remains high. 
• With the increasing numbers of long term survivors, late long term effects 
need to be monitored for. This necessitates robust systems for long term 
follow up in an adult setting. 
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Box 1.  Presenting features in acute leukaemia 
Bone marrow failure 
syndrome 
 
Anaemia Weakness, lethargy, pallor, shortness of breath 
Thrombocytopenia 
Easy bruising, bleeding e.g. nose & gums, petechiae,  
CNS bleeds causing spinal cord infarcts or other CNS infarcts 
(rare) 
Neutropenia Febrile illness, often with prolonged or unusual course 
Direct Infiltration 
 
Hepatic/Splenic Hepatosplenomegaly may cause pain from capsule stretch 
Medullary Bone pain (may also have periosteal infiltration) 
Central Nervous System 
Headache, meningism, cranial nerve palsies, numbness of the 
chin 
Cord compression in AML (from chloromas) (rare) 
Testicular Painless hard enlarged testis 
Thymus 
Superior vena cava syndrome with distended veins and 
facial/neck swelling, dyspnoea, cough (typical in T-ALL) 
Gum Classical of monocytic AML  
Skin Leukaemia cutis (typical in babies with monocytic AML) 
Soft tissues Chloroma formation in AML 
Other 
 
Leukostasis (WCC >100 
X 109/l - very rare) 
Poor perfusion of vital organs, pain from infarcts, priapism, 
visual disturbance 
Coagulopathy 
Classically seen in acute promyelocytic leukaemia, but also in 
other types of AML (e.g. monocytic leukaemias with a high cell 
count), potentially severe; 
CNS bleeds causing spinal cord infarcts or other CNS infarcts 
 18 
Box  2.  Differential diagnoses of leukaemia. 
Haematological 
 
Bone marrow failure 
Aplastic anaemia 
Myelodysplastic syndrome 
Inherited bone marrow failure syndromes e.g. Shwachman-
Diamond syndrome & Kostmann syndrome,  
Profound B12/folate deficiency 
Isolated cytopenias 
Idiopathic thrombocytopenia (ITP) 
Red cell aplasias e.g. Diamond-Blackfan anaemia 
Cyclical or autoimmune neutropenia 
Malignant 
 
Bone marrow infiltration 
Non-Hodgkin lymphoma, e.g. Burkitt lymphoma 
Neuroblastoma 
Rhabdomyosarcoma 
Other rarer tumour types 
Infectious 
 
Bacterial Severe sepsis resulting in coagulopathy and leukopenia 
Viral 
Parvovirus B19/Cytomegalovirus/Epstein Barr virus/Hepatitis 
viridae/HIV 
Rheumatological 
 
Rheumatoid arthritis Arthritides resulting in bone pain, anaemia and fever 
Osteomyelitis Bone pain, neutropenia and fever 
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Box 3.  General and specific side effects of cytotoxic drugs 
Side effects of most cytotoxic agents 
(incidence varies with differing drugs) 
 
Alopecia (temporary) Nausea & vomiting 
Myelosuppression Mucositis 
Impaired fertility  
Drug/Class specific  
 
Anthracyclines (e.g. doxorubicin, 
daunorubicin) 
Cardiac toxicity – acute and chronic, 
myocardial failure and dysrhythmias 
Asparaginase Allergic reactions/anaphylaxis 
Hepatitis/pancreatitis 
Venous thrombosis/coagulopathy 
ATRA ATRA syndrome – fever, respiratory infiltrates 
and distress, hypotension & leukocytosis 
Cytarabine (high dose) Chemical conjunctivitis 
Cerebellar ataxia 
Steroids Altered mood (common), psychosis (rare) 
Hyperphagia and weight gain 
Diabetes mellitus 
Avascular necrosis 
Etoposide Risk of induced secondary malignancy 
Methotrexate Hepatitis 
Marked mucositis 
Seizures (intrathecal administration) 
Vincristine Peripheral neurotoxicity – foot drop, constipation, 
jaw pain, neuropathic pain 
 
